Financhill
Sell
43

OCUL Quote, Financials, Valuation and Earnings

Last price:
$7.45
Seasonality move :
-5.75%
Day range:
$7.53 - $7.95
52-week range:
$4.06 - $11.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.72x
P/B ratio:
4.00x
Volume:
1.6M
Avg. volume:
1.4M
1-year change:
-16.07%
Market cap:
$1.3B
Revenue:
$63.7M
EPS (TTM):
-$1.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OCUL
Ocular Therapeutix
$16.9M -$0.22 16.58% -42.86% $17.50
ADMA
ADMA Biologics
$112.8M $0.15 41.07% 75% $25.27
CARA
Cara Therapeutics
$1.6M -$2.94 -73.37% -83.05% $12.00
EYPT
EyePoint Pharmaceuticals
$11M -$0.48 -24.38% -22.59% $33.00
OCGN
Ocugen
$300K -$0.05 -100% -- $6.75
TGTX
TG Therapeutics
$100.7M $0.20 84.44% -95.36% $42.83
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OCUL
Ocular Therapeutix
$7.94 $17.50 $1.3B -- $0.00 0% 19.72x
ADMA
ADMA Biologics
$18.67 $25.27 $4.4B 22.77x $0.00 0% 10.61x
CARA
Cara Therapeutics
$5.12 $12.00 $23.4M -- $0.00 0% 3.27x
EYPT
EyePoint Pharmaceuticals
$6.63 $33.00 $455.7M -- $0.00 0% 8.63x
OCGN
Ocugen
$0.57 $6.75 $167.2M -- $0.00 0% 38.26x
TGTX
TG Therapeutics
$41.06 $42.83 $6.4B 293.29x $0.00 0% 19.55x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OCUL
Ocular Therapeutix
17.85% 3.384 5.09% 10.26x
ADMA
ADMA Biologics
17.17% 4.789 1.78% 2.76x
CARA
Cara Therapeutics
-- -3.732 -- 10.67x
EYPT
EyePoint Pharmaceuticals
-- -2.597 -- 7.57x
OCGN
Ocugen
49.18% 4.395 12.22% 2.71x
TGTX
TG Therapeutics
52.36% 3.612 5.21% 4.85x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OCUL
Ocular Therapeutix
$15.9M -$50.6M -51.22% -62.66% -265.09% -$39.6M
ADMA
ADMA Biologics
$63.3M $38.3M 60.85% 93.41% 31.98% $23.9M
CARA
Cara Therapeutics
$1.5M -$5.5M -374.56% -374.56% -374.98% -$4M
EYPT
EyePoint Pharmaceuticals
$10.8M -$45.2M -50.34% -50.34% -356.36% -$36.2M
OCGN
Ocugen
-- -$13.8M -136.46% -171.04% -1811.52% -$10.4M
TGTX
TG Therapeutics
$92.8M $29.9M 6.86% 12.81% 30.05% -$25.7M

Ocular Therapeutix vs. Competitors

  • Which has Higher Returns OCUL or ADMA?

    ADMA Biologics has a net margin of -283.27% compared to Ocular Therapeutix's net margin of 95.19%. Ocular Therapeutix's return on equity of -62.66% beat ADMA Biologics's return on equity of 93.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    92.8% -$0.29 $383.8M
    ADMA
    ADMA Biologics
    53.88% $0.46 $421.4M
  • What do Analysts Say About OCUL or ADMA?

    Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 120.4%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 35.36%. Given that Ocular Therapeutix has higher upside potential than ADMA Biologics, analysts believe Ocular Therapeutix is more attractive than ADMA Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    5 0 0
    ADMA
    ADMA Biologics
    4 0 0
  • Is OCUL or ADMA More Risky?

    Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.

  • Which is a Better Dividend Stock OCUL or ADMA?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or ADMA?

    Ocular Therapeutix quarterly revenues are $17.1M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Ocular Therapeutix's net income of -$48.4M is lower than ADMA Biologics's net income of $111.9M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 22.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.72x versus 10.61x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    19.72x -- $17.1M -$48.4M
    ADMA
    ADMA Biologics
    10.61x 22.77x $117.5M $111.9M
  • Which has Higher Returns OCUL or CARA?

    Cara Therapeutics has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -527.77%. Ocular Therapeutix's return on equity of -62.66% beat Cara Therapeutics's return on equity of -374.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    92.8% -$0.29 $383.8M
    CARA
    Cara Therapeutics
    70.96% -$1.73 -$4.6M
  • What do Analysts Say About OCUL or CARA?

    Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 120.4%. On the other hand Cara Therapeutics has an analysts' consensus of $12.00 which suggests that it could grow by 134.36%. Given that Cara Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Cara Therapeutics is more attractive than Ocular Therapeutix.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    5 0 0
    CARA
    Cara Therapeutics
    0 1 0
  • Is OCUL or CARA More Risky?

    Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison Cara Therapeutics has a beta of 0.499, suggesting its less volatile than the S&P 500 by 50.057%.

  • Which is a Better Dividend Stock OCUL or CARA?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Cara Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or CARA?

    Ocular Therapeutix quarterly revenues are $17.1M, which are larger than Cara Therapeutics quarterly revenues of $1.5M. Ocular Therapeutix's net income of -$48.4M is lower than Cara Therapeutics's net income of -$7.7M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Cara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.72x versus 3.27x for Cara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    19.72x -- $17.1M -$48.4M
    CARA
    Cara Therapeutics
    3.27x -- $1.5M -$7.7M
  • Which has Higher Returns OCUL or EYPT?

    EyePoint Pharmaceuticals has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -357.26%. Ocular Therapeutix's return on equity of -62.66% beat EyePoint Pharmaceuticals's return on equity of -50.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    92.8% -$0.29 $383.8M
    EYPT
    EyePoint Pharmaceuticals
    92.96% -$0.64 $336.5M
  • What do Analysts Say About OCUL or EYPT?

    Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 120.4%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 397.74%. Given that EyePoint Pharmaceuticals has higher upside potential than Ocular Therapeutix, analysts believe EyePoint Pharmaceuticals is more attractive than Ocular Therapeutix.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    5 0 0
    EYPT
    EyePoint Pharmaceuticals
    9 0 0
  • Is OCUL or EYPT More Risky?

    Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.932%.

  • Which is a Better Dividend Stock OCUL or EYPT?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or EYPT?

    Ocular Therapeutix quarterly revenues are $17.1M, which are larger than EyePoint Pharmaceuticals quarterly revenues of $11.6M. Ocular Therapeutix's net income of -$48.4M is lower than EyePoint Pharmaceuticals's net income of -$41.4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.72x versus 8.63x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    19.72x -- $17.1M -$48.4M
    EYPT
    EyePoint Pharmaceuticals
    8.63x -- $11.6M -$41.4M
  • Which has Higher Returns OCUL or OCGN?

    Ocugen has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -1816.75%. Ocular Therapeutix's return on equity of -62.66% beat Ocugen's return on equity of -171.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    92.8% -$0.29 $383.8M
    OCGN
    Ocugen
    -- -$0.05 $58.3M
  • What do Analysts Say About OCUL or OCGN?

    Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 120.4%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1078.83%. Given that Ocugen has higher upside potential than Ocular Therapeutix, analysts believe Ocugen is more attractive than Ocular Therapeutix.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    5 0 0
    OCGN
    Ocugen
    2 0 0
  • Is OCUL or OCGN More Risky?

    Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.

  • Which is a Better Dividend Stock OCUL or OCGN?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or OCGN?

    Ocular Therapeutix quarterly revenues are $17.1M, which are larger than Ocugen quarterly revenues of $764K. Ocular Therapeutix's net income of -$48.4M is lower than Ocugen's net income of -$13.9M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.72x versus 38.26x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    19.72x -- $17.1M -$48.4M
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M
  • Which has Higher Returns OCUL or TGTX?

    TG Therapeutics has a net margin of -283.27% compared to Ocular Therapeutix's net margin of 21.57%. Ocular Therapeutix's return on equity of -62.66% beat TG Therapeutics's return on equity of 12.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    92.8% -$0.29 $383.8M
    TGTX
    TG Therapeutics
    85.77% $0.15 $466.8M
  • What do Analysts Say About OCUL or TGTX?

    Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 120.4%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 4.32%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    5 0 0
    TGTX
    TG Therapeutics
    5 0 0
  • Is OCUL or TGTX More Risky?

    Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.

  • Which is a Better Dividend Stock OCUL or TGTX?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or TGTX?

    Ocular Therapeutix quarterly revenues are $17.1M, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Ocular Therapeutix's net income of -$48.4M is lower than TG Therapeutics's net income of $23.3M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 293.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.72x versus 19.55x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    19.72x -- $17.1M -$48.4M
    TGTX
    TG Therapeutics
    19.55x 293.29x $108.2M $23.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock